Compound ID | 2890

Update compound information

LBP-EC01

Class: Bacteriophage and/or bacteriophage-derived product

Spectrum of activity: Gram-negative
Details of activity: Active against Escherichia coli
Description: A CRISPR-engineered bacteriophage for treatment of urinary tract infection
Institute where first reported: Locus Biosciences
Year first mentioned: 2022
Highest developmental phase: Phase 2 (NCT05488340)
Development status: Active (as of 2025)
External links:
Citations:
  • https://clinicaltrials.gov/study/NCT05488340
  • https://www.locus-bio.com/locus-biosciences-announces-first-patient-treated-in-the-eliminate-registrational-phase-2-3-trial-of-lbp-ec01-for-urinary-tract-infections/
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644767/

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.